Johnson & Johnson is to “proactively delay” the rollout of its Covid-19 vaccine to Europe as US health agencies recommended a precautionary pause in the use of the jab.
The Food and Drugs Administration (FDA) and the Centres for Disease Control and Prevention (CDC) earlier issued a joint statement to recommend the vaccine be paused “out of an abundance of caution” after six cases of a rare type of blood clot were reported.
The agencies said that six people who experienced the clots were between the ages of 18 and 48, were women, and that symptoms occurred 6 to 13 days after vaccination.
The company itself has said that it will be working with authorities in both the US and Europe in regard to the reported blood clots.
This will come as a second blow in two days for Ireland, having just yesterday decided to only administer the AstraZeneca vaccine to those over 60-years-old.